Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

AbbVie Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Net earnings (loss) (23) 1,564 1,373 1,372 824 1,781 2,027 241 2,472 3,952 928 4,493 4,045 3,180 769 3,555 38 2,313 (739) 3,010
Depreciation 206 191 184 183 187 196 190 179 196 181 203 198 173 223 201 206 227 175 149 115
Amortization of intangible assets 1,896 1,888 1,947 1,891 1,889 2,039 2,070 1,948 1,961 2,024 1,849 1,855 1,806 1,904 1,999 2,009 1,838 2,117 1,406 444
Deferred income taxes (767) (277) (16) (389) (1,391) (863) (368) (267) (516) (621) (600) (194) (745) (34) (91) (28) (1,827) (241) (76) (181)
Change in fair value of contingent consideration liabilities 279 1,356 1,476 660 1,696 8 1,552 1,872 2,114 (214) 1,609 (748) 232 98 2,692 (343) 4,675 197 809 72
Payments of contingent consideration liabilities (539) (580) (485) (391) (463) (391) (2) (14) (3) (161)
Stock-based compensation 164 181 218 348 125 130 179 313 132 126 107 306 129 135 159 269 136 162 236 219
Acquired IPR&D and milestones 1,574 82 937 164 282 66 280 150 243 40 269 145 405 402 132 185 348 85 903 40
Other charges related to collaborations 500
Gain on divestitures (172) (68)
Non-cash litigation reserve adjustments, net of cash payments 167 314 27 (238) (87) (118) (18) 71 2,190 142 (76) 97
Impairment of intangible assets 4,476 1,405 2,114 710 770 50
Other, net 12 (22) (8) (45) (6) (46) (45) (128) 1 (65) (214) 128 (28) (155) (10) (20) 341 57 433 1
Accounts receivable 387 344 178 (702) 339 2 (80) (195) (416) 357 (611) (785) (749) 590 (296) (866) (355) (31) 482 (1,025)
Inventories (128) (64) (52) (75) 96 (55) (273) (185) (170) (17) (114) (385) (112) 219 (62) (187) 153 111 (197) (107)
Prepaid expenses and other assets (100) 152 25 284 (582) 109 452 (167) (204) (74) 299 (285) 265 (181) 49 (330) (56) (50) 229 11
Accounts payable and other liabilities 1,247 267 (1,699) 362 179 2,538 1,574 (451) 1,278 939 (190) (258) 174 1,146 72 236 (389) 1,437 (559) 1,025
Income tax assets and liabilities, net (1,803) 51 (1,834) 378 411 33 (1,119) 187 358 294 (548) 438 (662) (66) (753) 191 (275) (502) 13 191
Changes in operating assets and liabilities, net of acquisitions (397) 750 (3,382) 247 443 2,627 554 (811) 846 1,499 (1,164) (1,275) (1,084) 1,708 (990) (956) (922) 965 (32) 95
Adjustments to reconcile net earnings (loss) to net cash from operating activities 7,071 3,883 898 2,668 3,929 5,793 4,292 3,952 4,956 3,650 4,077 415 1,030 4,755 4,121 1,322 4,816 3,517 3,828 805
Cash flows from operating activities 7,048 5,447 2,271 4,040 4,753 7,574 6,319 4,193 7,428 7,602 5,005 4,908 5,075 7,935 4,890 4,877 4,854 5,830 3,089 3,815
Acquisition of businesses, net of cash acquired (8,294) (9,199) (255) (525) (122) (38,138)
Other acquisitions and investments (1,792) (199) (843) (190) (553) (157) (160) (353) (45) (100) (209) (185) (540) (492) (147) (198) (278) (880) (180) (12)
Acquisitions of property and equipment (291) (249) (241) (193) (205) (219) (178) (175) (213) (177) (143) (162) (187) (217) (195) (188) (279) (217) (177) (125)
Purchases of investment securities (27) (24) (16) (6) (34) (8) (16) (19) (10) (17) (5) (1,406) (46) (17) (40) (16) (14) (15) (19) (13)
Sales and maturities of investment securities 39 507 3 6 14 5 14 22 70 1,410 42 8 10 23 54 11 61 35 1,403 26
Other, net 197 3 (5) (6) (22) 10 (1) 26 5 170 445 154 143 88 86 49 5 (72) 1,459 (5)
Cash flows from investing activities (1,874) (8,256) (1,102) (9,588) (800) (369) (341) (499) (448) 1,286 130 (1,591) (1,145) (615) (242) (342) (627) (1,149) (35,652) (129)
Proceeds from issuance of other short-term borrowings 5,008
Repayments of other short-term borrowings (3) (5,005)
Proceeds from issuance of long-term debt 2,000 14,963 2,000 1,000 3,000
Repayments of long-term debt and finance lease obligations (5,762) (403) (3,345) (103) (1,794) (2) (1,002) (1,351) (6,851) (2,701) (2) (4,879) (3,752) (2,201) (3,461) (1,269) (651) (3,763)
Debt issuance costs (99) (38) (20)
Dividends paid (2,752) (2,751) (2,750) (2,772) (2,626) (2,627) (2,625) (2,661) (2,506) (2,504) (2,507) (2,526) (2,314) (2,315) (2,310) (2,322) (2,101) (2,100) (1,752) (1,763)
Purchases of treasury stock (358) (17) (9) (1,324) (3) (4) (10) (1,955) (4) (4) (9) (1,470) (131) (6) (10) (787) (296) (20) (19) (643)
Proceeds from the exercise of stock options 10 67 10 127 31 36 48 65 53 11 70 128 75 25 73 71 100 32 65 12
Payments of contingent consideration liabilities (17) (94) (330) (311) (315) (335) (236) (246) (218) (167) (181) (132) (109) (83) (76) (53)
Other, net 1 32 24 (2) 30 (1) 21 (11) 15 5 21 2 21 5 (4) (20) 8 (5) 25
Cash flows from financing activities (6,861) (3,072) (6,097) 10,819 (4,449) (2,661) (3,920) (6,192) (9,634) (5,518) (2,679) (6,972) (6,338) (3,643) (5,884) (3,174) (3,695) (2,814) (2,570) (2,422)
Effect of exchange rate changes on cash and equivalents (46) 8 (9) (18) 23 (16) (10) 8 23 (59) (33) 7 (28) (41) 27 (55) 27 6 8 (46)
Net change in cash and equivalents (1,733) (5,873) (4,937) 5,253 (473) 4,528 2,048 (2,490) (2,631) 3,311 2,423 (3,648) (2,436) 3,636 (1,209) 1,306 559 1,873 (35,125) 1,218

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Cash flow statement item Description The company
Cash flows from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. AbbVie Inc. cash flows from operating activities increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Cash flows from investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. AbbVie Inc. cash flows from investing activities decreased from Q2 2024 to Q3 2024 but then increased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Cash flows from financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. AbbVie Inc. cash flows from financing activities increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.